Serological diagnosis of atrophic gastritis with a combination of pepsinogen I and II, gastrin-17 and anti-Helicobacter pylori antibodies;Diagnóstico serológico de gastritis atrófica con una combinación de pepsinógeno I y II, gastrina-17 y anticuerpos anti-Helicobacter pylori

Gastroenterologia y Hepatologia

Volumn 30, Issue 10, 2007, Pages 567-571

  Valle Muñoz, Julio ^a   Artaza Varasa, Tomás ^a   López Pardo, Rafael ^a   Rodríguez Merlo, Rufo ^a   Pérez Grueso, María José ^a   Martín Escobedo, Roberto ^a   Alcántara Torres, Mariano ^a   Cuena Boy, Rafael ^a   Carrobles Jiménez, José María ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; GASTRIN 17 ANTIBODY; HORMONE ANTIBODY; PEPSINOGEN I ANTIBODY; PEPSINOGEN II ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; BLOOD SAMPLING; CONTROLLED STUDY; DYSPEPSIA; ENZYME IMMUNOASSAY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; SCREENING TEST; SEROLOGY; STOMACH ANTRUM; STOMACH CARCINOMA;

EID: 37149013577     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13112584     Document Type: Article

References (29)

1. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans. Genève: World Health Organisation;1994. p. 1-241.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-86.
3. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347-53.
4. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-40.
5. Rugge M, Genta RM. Staging Gastritis: an international proposal [letter]. Gastroenterology. 2005;129:1807-8.
6. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985;15;35:173-7.
7. Dixon MF, Genta RM, Yardley J et al. Clasification and grading of gastritis: the up-dated Sydney System. International Workshop on the Histology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-81.
8. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36:228-33.
9. Sipponen P, Harkonen M, Alanko A, Suovaniemi O. Diagnosis of atrophic gastritis from a serum sample. Clin Lab. 2002;48:505-15.
10. Vaananen H, Vauhkonen M, Helske T, Kaariainen I, Rasmussen M, Tunturi-Hihnala H, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003;15:885-91.
11. Germana B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, et al. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis. 2005;37:501-8.
12. Hartleb M, Wandzel P, Waluga M, Matyszczyk B, Boldys H, Romanczyk T. Non-endoscopic diagnosis of multifocal atrophic gastritis; efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies. Acta Gastroenterol Belg. 2004;67:320-6.
13. Pérez-Grueso MJ, Valle J, González de Frutos C, Artaza T, Rodríguez-Merlo R, Alcántara M, et al. Características clínico-patológicas de la dispepsia no investigada en España. Gastroenterol Hepatol. 2007;30:1-6.
14. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
15. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter. 2001;6:294-9.
16. Hu PJ, Li YY, Lin HL, Zhou SM, Du G, Chen MH, et al. Gastric atrophy and regional variation in upper gastrointestinal disease. Am J Gastroenterol. 1995;90:1102-6.
17. Recavarren-Arce S, Gilman RH, León-Barua R, Salazar G, McDonald J, Lozano R, et al. Chronic atrophic gastritis: early diagnosis in a population where Helicobacter pylori infection is frequent. Clin Infect Dis. 1997;25:1006-12.
18. Sipponen P, Helske T, Jarvinen P, Hyvarinen H, Seppala K, Siurala M. Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. Gut. 1994;35:1167-71.
19. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Longterm course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996;31:546-50.
20. Sipponen P, Kekki M, Siurala M. Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample. Cancer. 1983;52:1062-8.
21. Valle J, Pikkarainen P, Vuoristo M, Sipponen P, Kekki M, Siurala M. Helicobacter pylori and duodenal ulcer. A study of duodenal ulcer patients and their first-degree relatives. Scand J Gastroenterol. 1991;26 Suppl 186:45-51.
22. Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter pylori Study Group. Current concepts in the management of H. pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-80.
23. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-94.
24. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53:1244-9.
25. Calvet X. Tratamiento erradicador de Helicobacter pylori en la enfermedad no ulcerosa. Gastroenterol Hepatol. 2005;28:40-6.
26. Genta RM, Pusztaszeri M. The gastric mucosa in gastric cancer patients in a low-incidence area. Eur J Gastroenterol Hepatol. 2006;18:1085-93.
27. Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice. Eur J Gastroenterol Hepatol. 2000;12:319-25.
28. Bowie PE, Cox RA, Davidson AR, Steel A. Young dyspeptic patients: with a test-and-treat policy, are the benefits of decreased symptom severity and oesophago-gastric-duodenoscopy workload sustained? Eur J Gastroenterol Hepatol. 2001;13:541-5.
29. Kokkola A, Rautelin H, Puolakkainen P, Sipponen P, Farkkila M, Haapiainen R, et al. Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. Scand J Gastroenterol. 2000;35:138-41.